Substance Abuse Treatment Unit
New Haven, Connecticut, 06519, United States
NCT Number: NCT00104598
This is a randomized study of message framing in individuals beginning a smoking cessation program utilizing bupropion SR and brief counseling, videos, and pamphlets.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Not applicable
New Haven, Connecticut, 06519, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Exclusion criteria
This investigation was a randomized controlled study of two framed message conditions for smoking cessation in combination with open label bupropion SR (300 mg/day). Two hundred fifty-eight cigarette smokers were randomly assigned to receive either gain- or loss-framed video and printed messages encouraging smoking abstinence. Preproduced video and printed information were chosen as the intervention media because of their reliability in delivering specific framed messages. All participants were seen at a community mental health center for 6 months and received a 7-week supply of bupropion SR.
Time frame: 7-day point prevalence abstinence
Time frame: 6 weeks
6-week continuous abstinence.
Yale University
Other
Framing Messages for Smoking Cessation With Buproprion
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07737288
Behavior, Chemically-Induced Disorders
Izmir, Turkey (Türkiye)
View Trial DetailsNCT03950427
Behavior, Chemically-Induced Disorders
San Francisco, California, United States
View Trial DetailsNCT04417595
Chemically-Induced Disorders, Female Urogenital Diseases and Pregnancy Complications
Nashville, Tennessee, United States
View Trial DetailsNCT04033237
Chemically-Induced Disorders, Mental Disorders
Lexington, Kentucky, United States
View Trial Details